Atibuclimab injected into the knee for knee osteoarthritis
Tests atibuclimab against placebo injected into the knee in people with knee osteoarthritis.
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Pilot and Feasibility Study of Anti-CD14 for the Treatment of Knee Osteoarthritis
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 40 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Atibuclimab
- saline placebo
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 80 with painful knee osteoarthritis and fluid in the knee joint. It tests atibuclimab (anti-CD14) against a saline placebo.
- Age
- 50 to 80 years
- Sex
- All sexes
- Disease stage
- Knee osteoarthritis by ACR classification criteria, Kellgren-Lawrence grade above 1, pain of 5 or more on a Visual Analogue Scale, and fluid in the knee (joint effusion) on exam.
- Earlier treatment
- No corticosteroid injection in the affected knee within 3 months. No viscosupplementation or other knee-joint injection within 6 months. No knee replacement in either knee.
Main reasons for not taking part
- Serious infection, or infection needing hospital care, in the last 1 year
- Fibromyalgia, rheumatoid arthritis, psoriatic arthritis, or poorly controlled crystal arthritis in the last 6 months
- Pregnancy or breastfeeding
- Heart failure with symptoms, glomerular filtration rate (kidney function) below 45, BMI above 40 kg/m2, or A1c above 8% (64 mmol/mol)
- Cancer treated with chemotherapy, radiation or surgery within 3 months, or unable to walk without a walking aid
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- ACR Classification Criteria for Knee Osteoarthritis
- Pain >=5 on Visual Analogue Scale
- Kelgren-Lawrence Grade >1
- Joint Effusion on Exam
- Able to provide informed consent
Who cannot take part
- Receipt of corticosteroid in affected knee within 3 months
- Receipt of visco-supplementation or other intra-articular therapy (other than corticosteroid) within 6 months
- Serious or hospitalized infection in last 1 year
- History of diagnosed fibromyalgia
- History of knee arthroplasty in either knee
- Symptomatic heart failure
- Recent active malignancy (chemotherapy, radiation, or surgery within 3 months)
- Poorly controlled diabetes (A1c>8%)
- Poorly controlled crystal arthritis in last 6 months
- Pain Pressure Threshold (PPT) testing <=3
- Ongoing participation in another interventional study
- Inability to ambulate without assistive device
- Pregnancy or Lactation
- Glomerular filtration rate <45
- Class III obesity (BMI>40 kg/m2)
- Rheumatoid Arthritis
- Psoriatic Arthritis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Where in United States
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, United StatesContact: Joshua F Baker, MD MSCENot yet recruiting
About the trial
What the trial wants to find out
Knee osteoarthritis (KOA) is a leading cause of chronic pain and disability among Veterans, which contributes significantly to reduced mobility, impaired quality of life, and increased health care utilization. First-line therapies, including non-steroidal anti-inflammatory drugs, physical therapy, and intra-articular corticosteroids, provide modest and short-term relief, while being associated with other side effects (i.e., potential for hastened cartilage loss) and no disease-modifying potential. Total knee arthroplasty, although effective, is not suitable for all patients and carries surgical risks. There is an unmet need for effective, durable, and locally-targeted therapies that can alleviate pain and improve function. The development of new therapies for this condition is thus a priority for the VA.
Read full original descriptionShow less
While the therapy has been used in humans in other contexts, to date there are no data on the safety, feasibility, and potential efficacy IC14 administration in patients with KOA. A small-scale, Phase I pilot and feasibility trial is therefore critical to inform the design and implementation of larger, definitive studies. Specifically, preliminary data are needed to (1) determine the appropriate inclusion/exclusion criteria, (2) solidify the study design and study processes,(3) assess patient tolerance and acceptability of i.a. mAb infusion for KOA, (4) evaluate safety profiles of the localized biologic intervention. Participants will be randomized into one of two arms, (a placebo arm, and active atibuclimab arm (2 mg/kg)) and will be followed to evaluate the safety and feasibility of this treatment.
The 2 groups in the trial
- Atibuclimab 20 mg/kgTreatment being tested
IV infusion of atibuclimab
Treatment: Atibuclimab
- Placebo (saline only)Placebo, for comparison
placebo infusion of saline
Treatment: saline placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot and Feasibility Study of Intra-articular Anti-CD14 for the Treatment of Knee Osteoarthritis
- Plain-language title
- Atibuclimab injected into the knee for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07481474, who can take part
- Record updated
- 15 July 2026